Aquestive Therapeutics (AQST) Non-Current Assets: 2017-2025

Historic Non-Current Assets for Aquestive Therapeutics (AQST) over the last 8 years, with Sep 2025 value amounting to $11.9 million.

  • Aquestive Therapeutics' Non-Current Assets fell 11.22% to $11.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.9 million, marking a year-over-year decrease of 11.22%. This contributed to the annual value of $13.2 million for FY2024, which is 19.74% down from last year.
  • Latest data reveals that Aquestive Therapeutics reported Non-Current Assets of $11.9 million as of Q3 2025, which was down 0.76% from $12.0 million recorded in Q2 2025.
  • In the past 5 years, Aquestive Therapeutics' Non-Current Assets ranged from a high of $17.6 million in Q1 2023 and a low of $11.9 million during Q3 2025.
  • Over the past 3 years, Aquestive Therapeutics' median Non-Current Assets value was $13.6 million (recorded in 2024), while the average stood at $14.7 million.
  • As far as peak fluctuations go, Aquestive Therapeutics' Non-Current Assets spiked by 34.37% in 2023, and later decreased by 21.21% in 2024.
  • Over the past 5 years, Aquestive Therapeutics' Non-Current Assets (Quarterly) stood at $14.7 million in 2021, then increased by 16.61% to $17.2 million in 2022, then dropped by 4.25% to $16.5 million in 2023, then fell by 19.74% to $13.2 million in 2024, then declined by 11.22% to $11.9 million in 2025.
  • Its Non-Current Assets was $11.9 million in Q3 2025, compared to $12.0 million in Q2 2025 and $13.1 million in Q1 2025.